Your chance to get on the next “60-Second Trade”

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

SGMO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Sangamo Therapeutics Insider Trading History Chart

Sangamo Therapeutics Share Price & Price History

^$1.13

▲ +0.11 (10.78%)

As of 01/2/2025 06:45 PM ET

Days: 30 | 90 | 365

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Sangamo Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/26/2023	Biogen Inc.	Major Shareholder	Sell	6,000,000	$0.50	$3,000,000.00	17,652,466
8/29/2022	Biogen Inc.	Major Shareholder	Sell	400,000	$5.33	$2,132,000.00	23,752,466
6/3/2022	John Markels	Director	Buy	6,784	$3.69	$25,032.96	32,484

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

SEC Filings (Institutional Ownership Changes) for Sangamo Therapeutics (NASDAQ:SGMO)

56.93% of Sangamo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Sangamo Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/20/2024	Virtu Financial LLC	172,665	$0.15M	0.0%	N/A	0.083%
11/16/2024	Geode Capital Management LLC	2,138,309	$1.85M	0.0%	+14.6%	1.025%
11/15/2024	XTX Topco Ltd	103,716	$90K	0.0%	+167.8%	0.050%
11/15/2024	State Street Corp	664,621	$0.58M	0.0%	+28.0%	0.319%
11/15/2024	Jacobs Levy Equity Management Inc.	1,471,717	$1.28M	0.0%	-50.1%	0.705%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	108,877	$94K	0.0%	-56.1%	0.052%
11/14/2024	Wasatch Advisors LP	19,442,368	$16.84M	0.1%	-3.2%	9.337%
11/13/2024	FMR LLC	544,003	$0.47M	0.0%	+16.5%	0.261%
11/12/2024	Charles Schwab Investment Management Inc.	1,103,326	$0.96M	0.0%	+5.5%	0.530%
11/12/2024	Massachusetts Financial Services Co. MA	193,762	$0.17M	0.0%	-2.4%	0.093%
11/5/2024	GSA Capital Partners LLP	345,632	$0.30M	0.0%	-63.0%	0.166%
11/4/2024	Meritage Portfolio Management	85,000	$74K	0.0%	+8.6%	0.041%
10/25/2024	Golden State Equity Partners	266,484	$0.23M	0.1%	+35.2%	0.128%
10/24/2024	Wealth Enhancement Advisory Services LLC	108,945	$94K	0.0%	+55.4%	0.052%
10/16/2024	Vontobel Holding Ltd.	300,000	$0.26M	0.0%	+412.3%	0.145%
9/16/2024	Cubist Systematic Strategies LLC	185,813	$67K	0.0%	N/A	0.089%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	247,866	$89K	0.0%	N/A	0.119%
8/15/2024	Armistice Capital LLC	14,060,000	$5.04M	0.1%	-17.1%	6.752%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	247,866	$89K	0.0%	N/A	0.119%
8/14/2024	Cubist Systematic Strategies LLC	185,813	$67K	0.0%	N/A	0.089%
8/14/2024	Marshall Wace LLP	576,219	$0.21M	0.0%	+56.3%	0.277%
8/9/2024	Renaissance Technologies LLC	4,126,577	$1.48M	0.0%	+58.8%	1.989%
8/9/2024	Dimensional Fund Advisors LP	518,203	$0.19M	0.0%	-6.3%	0.250%
8/6/2024	Acadian Asset Management LLC	4,560,770	$1.63M	0.0%	-7.7%	2.198%
5/16/2024	Jacobs Levy Equity Management Inc.	191,949	$0.13M	0.0%	-81.0%	0.093%
5/10/2024	Acadian Asset Management LLC	4,943,260	$3.31M	0.0%	+4.0%	2.382%
5/10/2024	Vanguard Group Inc.	12,200,368	$8.18M	0.0%	-3.2%	5.880%
5/9/2024	State Board of Administration of Florida Retirement System	62,345	$42K	0.0%	+61.1%	0.030%
5/7/2024	SG Americas Securities LLC	58,584	$39K	0.0%	-67.6%	0.028%
5/1/2024	BNP Paribas Financial Markets	72,160	$48K	0.0%	-82.9%	0.035%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	493,431	$0.33M	0.0%	N/A	0.238%
4/18/2024	Wasatch Advisors LP	20,132,324	$13.49M	0.1%	+62.4%	11.253%
2/14/2024	Wasatch Advisors LP	12,397,924	$6.74M	0.0%	-31.1%	6.991%
2/2/2024	Golden State Equity Partners	201,225	$0.11M	0.0%	+21.0%	0.113%
1/31/2024	Federated Hermes Inc.	340,693	$0.19M	0.0%	-23.3%	0.192%
1/30/2024	Mackenzie Financial Corp	73,799	$40K	0.0%	+72.4%	0.042%
1/17/2024	Assenagon Asset Management S.A.	1,033,322	$0.56M	0.0%	+14.4%	0.583%
1/12/2024	SG Americas Securities LLC	180,544	$98K	0.0%	+103.9%	0.102%
12/19/2023	Public Employees Retirement System of Ohio	50,200	$30K	0.0%	-86.2%	0.028%
12/7/2023	Hudson Bay Capital Management LP	1,298,500	$0.78M	0.0%	-2.0%	0.732%
11/13/2023	Acadian Asset Management LLC	2,927,769	$1.75M	0.0%	+3.7%	1.651%
11/8/2023	Vanguard Personalized Indexing Management LLC	43,057	$26K	0.0%	N/A	0.024%
10/26/2023	Mirae Asset Global Investments Co. Ltd.	676,189	$0.41M	0.0%	+10.2%	0.382%
10/25/2023	Miracle Mile Advisors LLC	41,300	$25K	0.0%	N/A	0.023%
10/20/2023	Golden State Equity Partners	166,265	$100K	0.0%	+22.5%	0.094%
10/17/2023	DAVENPORT & Co LLC	47,100	$28K	0.0%	-31.0%	0.027%
10/13/2023	SG Americas Securities LLC	88,542	$53K	0.0%	+255.2%	0.050%
8/14/2023	Graham Capital Management L.P.	67,748	$88K	0.0%	N/A	0.038%
8/11/2023	Penserra Capital Management LLC	99,352	$0.13M	0.0%	+163.5%	0.056%
8/11/2023	ExodusPoint Capital Management LP	2,083,633	$2.71M	0.0%	+59.1%	1.176%
8/10/2023	Mirae Asset Global Investments Co. Ltd.	613,724	$0.80M	0.0%	+16.8%	0.357%
8/8/2023	Wasatch Advisors LP	17,052,440	$22.17M	0.1%	+25.0%	9.924%
8/7/2023	Principal Financial Group Inc.	50,889	$66K	0.0%	+30.1%	0.030%
8/7/2023	Acadian Asset Management LLC	2,821,980	$3.67M	0.0%	+502.7%	1.642%
8/3/2023	Mackenzie Financial Corp	30,568	$41K	0.0%	N/A	0.018%
8/1/2023	Fort Sheridan Advisors LLC	66,486	$86K	0.0%	+15.0%	0.039%
8/1/2023	Cookson Peirce & Co. Inc.	50,000	$65K	0.0%	N/A	0.029%
7/25/2023	Raymond James Financial Services Advisors Inc.	40,103	$52K	0.0%	-46.0%	0.023%
7/24/2023	Allspring Global Investments Holdings LLC	46,408	$60K	0.0%	+278.8%	0.027%
7/24/2023	Vontobel Holding Ltd.	30,560	$40K	0.0%	-56.7%	0.018%
7/20/2023	DAVENPORT & Co LLC	68,300	$89K	0.0%	-12.4%	0.040%
7/18/2023	Diversified Trust Co	25,740	$33K	0.0%	N/A	0.015%
7/18/2023	Allspring Global Investments Holdings LLC	46,408	$60K	0.0%	+278.8%	0.027%
7/10/2023	SG Americas Securities LLC	24,930	$32K	0.0%	-66.4%	0.015%
6/1/2023	Golden State Equity Partners	135,765	$0.24M	0.1%	N/A	0.079%
5/12/2023	Long Focus Capital Management LLC	639,372	$1.13M	0.1%	-40.4%	0.372%
5/12/2023	Rhenman & Partners Asset Management AB	314,157	$0.53M	0.1%	-61.7%	0.183%
5/11/2023	Acadian Asset Management LLC	468,239	$0.82M	0.0%	N/A	0.273%
5/11/2023	Cornercap Investment Counsel Inc.	86,934	$0.15M	0.0%	+28.0%	0.051%
5/11/2023	ExodusPoint Capital Management LP	1,309,323	$2.30M	0.0%	+496.5%	0.762%
5/10/2023	Credit Suisse AG	3,819,113	$6.72M	0.0%	+0.3%	2.227%
5/9/2023	Russell Investments Group Ltd.	195,906	$0.35M	0.0%	+93.3%	0.114%
5/8/2023	Federated Hermes Inc.	320,036	$0.56M	0.0%	+126.1%	0.187%
5/4/2023	Barclays PLC	379,016	$0.67M	0.0%	-24.0%	0.221%
5/4/2023	Mirae Asset Global Investments Co. Ltd.	525,280	$0.92M	0.0%	+5.6%	0.306%
5/1/2023	Banque Pictet & Cie SA	85,944	$0.15M	0.0%	-31.2%	0.050%
4/28/2023	SG Americas Securities LLC	74,156	$0.13M	0.0%	+42.3%	0.043%
4/19/2023	Nordea Investment Management AB	640,346	$1.11M	0.0%	-4.9%	0.373%
4/18/2023	Assenagon Asset Management S.A.	903,547	$1.59M	0.0%	+4.5%	0.527%
3/28/2023	Acrisure Capital Management LLC	31,673	$99K	0.1%	N/A	0.019%
3/23/2023	MetLife Investment Management LLC	55,073	$0.17M	0.0%	-17.6%	0.033%
2/15/2023	Avidity Partners Management LP	2,748,300	$8.63M	0.2%	+16.4%	1.677%
2/13/2023	Pinnacle Wealth Planning Services Inc.	14,386	$45K	0.0%	-40.3%	0.009%
2/13/2023	Credit Suisse AG	3,808,146	$11.96M	0.0%	+0.1%	2.324%
2/13/2023	GSA Capital Partners LLP	200,465	$0.63M	0.1%	+1,232.0%	0.122%
2/13/2023	Cornercap Investment Counsel Inc.	67,910	$0.21M	0.0%	+34.8%	0.041%
2/13/2023	Quadrant Capital Group LLC	12,734	$40K	0.0%	+848.9%	0.008%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	349,894	$1.10M	0.0%	-42.2%	0.214%
2/10/2023	Blair William & Co. IL	294,902	$0.93M	0.0%	-14.5%	0.180%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	497,306	$1.56M	0.0%	-21.8%	0.303%
2/9/2023	Citigroup Inc.	339,575	$1.07M	0.0%	-14.5%	0.207%
2/9/2023	HighTower Advisors LLC	1,030,958	$3.24M	0.0%	-11.3%	0.629%
2/8/2023	Raymond James Financial Services Advisors Inc.	80,083	$0.25M	0.0%	-5.0%	0.049%
2/8/2023	UBS Group AG	592,054	$1.86M	0.0%	+457.1%	0.361%
2/8/2023	Nordea Investment Management AB	673,398	$2.03M	0.0%	-1.3%	0.411%
2/8/2023	Swiss National Bank	321,260	$1.01M	0.0%	+9.7%	0.196%
2/8/2023	Arizona State Retirement System	37,549	$0.12M	0.0%	+10.8%	0.023%
2/7/2023	Handelsbanken Fonder AB	15,146	$48K	0.0%	N/A	0.009%
2/7/2023	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	69,610	$0.22M	0.0%	+12.8%	0.042%
2/6/2023	Los Angeles Capital Management LLC	18,076	$57K	0.0%	-83.3%	0.011%

Data available starting January 2016

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Today's Range

Now: $1.13

$0.97

$1.14

50 Day Range

MA: $2.14

$1.02

$2.87

52 Week Range

Now: $1.13

$0.30

$3.18

Volume

13,600,541 shs

Average Volume

7,095,709 shs

Market Capitalization

$235.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Who are the company insiders with the largest holdings of Sangamo Therapeutics?: Sangamo Therapeutics' top insider shareholders include:
Biogen Inc (Major Shareholder)
Learn More about top insider investors at Sangamo Therapeutics.